These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9371155)

  • 1. Cerestat and other NMDA antagonists in ischemic stroke.
    Lees KR
    Neurology; 1997 Nov; 49(5 Suppl 4):S66-9. PubMed ID: 9371155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with excitatory amino acid antagonist drugs.
    Muir KW; Lees KR
    Stroke; 1995 Mar; 26(3):503-13. PubMed ID: 7886734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial.
    Albers GW; Goldstein LB; Hall D; Lesko LM;
    JAMA; 2001 Dec; 286(21):2673-82. PubMed ID: 11730442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise and fall of NMDA antagonists for ischemic stroke.
    Hoyte L; Barber PA; Buchan AM; Hill MD
    Curr Mol Med; 2004 Mar; 4(2):131-6. PubMed ID: 15032709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-methyl-D-aspartate antagonists for stroke and head trauma.
    Wood PL; Hawkinson JE
    Expert Opin Investig Drugs; 1997 Apr; 6(4):389-97. PubMed ID: 15989606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
    Ikonomidou C; Turski L
    Lancet Neurol; 2002 Oct; 1(6):383-6. PubMed ID: 12849400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate AMPA receptor antagonist treatment for ischaemic stroke.
    Akins PT; Atkinson RP
    Curr Med Res Opin; 2002; 18 Suppl 2():s9-13. PubMed ID: 12365832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excitatory amino acid antagonists for acute stroke.
    Muir KW; Lees KR
    Cochrane Database Syst Rev; 2003; 2003(3):CD001244. PubMed ID: 12917902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers.
    Muir KW; Grosset DG; Lees KR
    Clin Neuropharmacol; 1997 Aug; 20(4):311-21. PubMed ID: 9260729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of non-competitive N-methyl-D-aspartate receptor antagonism on cerebral oedema and cerebral infarct size in the aging ischaemic brain.
    Davis M; Perry RH; Mendelow AD
    Acta Neurochir Suppl; 1997; 70():30-3. PubMed ID: 9416269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke.
    Dyker AG; Edwards KR; Fayad PB; Hormes JT; Lees KR
    Stroke; 1999 Oct; 30(10):2038-42. PubMed ID: 10512904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of aptiganel HCl (Cerestat) following controlled cortical impact injury in the rat.
    Kroppenstedt SN; Schneider GH; Thomale UW; Unterberg AW
    J Neurotrauma; 1998 Mar; 15(3):191-7. PubMed ID: 9528919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers.
    Hu LY; Guo J; Magar SS; Fischer JB; Burke-Howie KJ; Durant GJ
    J Med Chem; 1997 Dec; 40(26):4281-9. PubMed ID: 9435897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of neuroprotectants in stroke.
    Lyden P; Wahlgren NG
    J Stroke Cerebrovasc Dis; 2000 Nov; 9(6 Pt 2):9-14. PubMed ID: 17895214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective properties of aptiganel HCL (Cerestat) following controlled cortical impact injury.
    Kroppenstedt SN; Schneider GH; Thomale UW; Unterberg AW
    Acta Neurochir Suppl; 1998; 71():114-6. PubMed ID: 9779160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.
    Grotta J; Clark W; Coull B; Pettigrew LC; Mackay B; Goldstein LB; Meissner I; Murphy D; LaRue L
    Stroke; 1995 Apr; 26(4):602-5. PubMed ID: 7709405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMDA receptor antagonists and glycine site NMDA antagonists.
    Madden K
    Curr Med Res Opin; 2002; 18 Suppl 2():s27-31. PubMed ID: 12365826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury.
    Wang CX; Shuaib A
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):143-51. PubMed ID: 15857299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective agents in acute ischemic stroke.
    Sareen D
    J Assoc Physicians India; 2002 Feb; 50():250-8. PubMed ID: 12038658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.